Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi.

Tweya, Hannock; Keiser, Olivia; Haas, Andreas D; Tenthani, Lyson Nemoni; Phiri, Sam; Egger, Matthias; Estill, Janne (2016). Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi. AIDS, 30(6), pp. 953-962. Lippincott Williams & Wilkins 10.1097/QAD.0000000000001009

Preview

Text Tweya AIDS 2016.pdf - Published Version Available under License Publisher holds Copyright. Download (2MB) | Preview

OBJECTIVE

To estimate the cost-effectiveness of prevention of mother-to-child transmission (MTCT) of HIV with lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women ('Option B+') compared with ART during pregnancy or breastfeeding only unless clinically indicated ('Option B').

DESIGN

Mathematical modelling study of first and second pregnancy, informed by data from the Malawi Option B+ programme.

METHODS

Individual-based simulation model. We simulated cohorts of 10 000 women and their infants during two subsequent pregnancies, including the breastfeeding period, with either Option B+ or B. We parameterized the model with data from the literature and by analysing programmatic data. We compared total costs of antenatal and postnatal care, and lifetime costs and disability-adjusted life-years of the infected infants between Option B+ and Option B.

RESULTS

During the first pregnancy, 15% of the infants born to HIV-infected mothers acquired the infection. With Option B+, 39% of the women were on ART at the beginning of the second pregnancy, compared with 18% with Option B. For second pregnancies, the rates MTCT were 11.3% with Option B+ and 12.3% with Option B. The incremental cost-effectiveness ratio comparing the two options ranged between about US$ 500 and US$ 1300 per DALY averted.

CONCLUSION

Option B+ prevents more vertical transmissions of HIV than Option B, mainly because more women are already on ART at the beginning of the next pregnancy. Option B+ is a cost-effective strategy for PMTCT if the total future costs and lost lifetime of the infected infants are taken into account.

Interest & Impact

Downloads

342 since deposited on 21 Apr 2016
44 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item